Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16051778 | 0.98 | PKM (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL23306876 | 0.76 | ADORA3 (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL20019155 | 0.74 | NPSR1 (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL504102 | 0.74 | NPSR1 (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL10238 | 0.74 | NPSR1 (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL23132987 | 0.74 | NPSR1 (0.53) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL84864 | 0.74 | NPSR1 (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL13325708 | 0.74 | NPC1 (0.50) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL3313454 | 0.74 | MIF (0.53) | PKMNPSR1FLT3ADORA3NPC1 | |
| SCHEMBL729145 | 0.74 | NPSR1 (0.50) | PKMNPSR1FLT3ADORA3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | claimed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | claimed |
| US-20040122044-A1 | Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations | GRUENENTHAL GMBH (DE) | 2004-06-24 | — | — | US | claimed |
| US-20260070905-A1 | Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity | UNIV DE VELENCIA (ES) | 2026-03-12 | — | — | US | disclosed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | US | disclosed |
| EP-4596548-A1 | NURR1 MODULATORS | Ludwig-Maximilians-Universität (DE) | 2025-08-06 | — | — | EP | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-119497615-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2025003545-A1 | DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE WITH ANTI-INFLAMMATORY ACTIVITY | UNIVERSITAT DE VALÈNCIA (ES) | 2025-01-02 | — | — | WO | disclosed |
| EP-1372644-A2 | USE OF SUBSTITUTED IMIDAZO 1,2-A]-PYRIDINE-3-YL-AMIDE AND IMIDAZO 1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002080911-A3 | USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMIDE AND IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | WO | disclosed |
| US-20030144518-A1 | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines | THE PROCTER & GAMBLE COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2002080911-A2 | USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMIDE AND IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Grünenthal GmbH (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002080911-A2 | USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMIDE AND IMIDAZO[1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Grünenthal GmbH (DE) | 2002-10-17 | — | — | WO | disclosed |
| US-5656634-A | N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5362878-A | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1994-11-08 | — | — | US | disclosed |
| WO-1991004027-A1 | NEW N-ARYL AND N-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT) | PFIZER INC. (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | PKM 992/4885NPSR1 4130/4885FLT3 1593/4885 |
| US-20030144518-A1 | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines | CBR1, PTGS1, CBR3 | PKM 3942/4885NPSR1 1581/4885FLT3 2235/4885 |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | TDP1, TDP2, TOP1 | PKM 2195/4885NPSR1 4684/4885FLT3 2495/4885 |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | PKM 3234/4885NPSR1 4247/4885FLT3 2071/4885 |
| US-20260070905-A1 | Derivatives of Imidazo[1,2-A]Pyridine with Anti-Inflammatory Activity | IL1A, IL6, IL1B | PKM 3423/4885NPSR1 1435/4885FLT3 4415/4885 |
| US-20040122044-A1 | Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations | NOS1, NAT1, NOS3 | PKM 530/4885NPSR1 410/4885FLT3 2106/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | PKM 85/4885NPSR1 1223/4885FLT3 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.